we presume that the synthesized derivatives may also be exhibiting a similar
cell death mechanism as that shown by 5-fluorouracil. All the results to this
regard are included in Tables 3 and 4.
References and notes
1
.
De Oliveira, C.S.; Lira, B.F.; Barbosa-Filho, J.M.; Lorenzo, J.G.F.; De
Athayde-Filho, P.F. Molecules. 2012, 17, 10192.
2
.
Spinelli, O.A. Ital. Soc. Chem. 1999, 3, 301.
Table 3. Anticancer activity of 1,3,4-oxadiazol-2-yl)-6-(trifluoro
3.
Conti, P.; Dallanoce, C,; Amici, M.D.; Micheli, C.D.; Klotz, K.N.
Bioorg. Med. Chem. 1998, 6, 401.
Mishra, a,; Jain, s.k.; Asthana, J.G. Orient. J. Chem. 1998, 14, 151.
Rigo, B.; Couturier D. J. Heterocyclic Chem. 1985, 22, 287.
Guimaraes, C.R.W.; Boger, D.L.; Jorgensen, W.L. J. Am. Chem. Soc.
methyl)pyridin-2-yl)alkyl /arylamide or pyridin-2-amine
4
5
6
.
.
.
(
6a-j) derivatives
2
005, 127, 17377.
IC50 values (μM)
7
.
Loetchutinat, C.; Chau,F.; Mankhetkorn, S. Chem. Pharm. Bull. 2003,
51, 728.
Test
compound
S.No
MDA-MB-
31
8.
Abadi, A.H.; Eissa, A.A.; Hassan, G.S. Chem. Pharm. Bull. 2003, 51,
838.
HeLa
DU145
HepG2
2
9
1
.
0.
Bhatia, S.; Gupta, M. J. Chem. Pharm. Res. 2011, 3, 137.
Kumar, D.; Sundaree, S.; Johnson, E.O.; Shah, K. Bioorg. Med. Chem.
Lett. 2009, 19, 4492.
Suresh Kumar, G.V.; Rajendraprasad, Y.; Mallikarjuna, B.P.;
Chandrashekar, S.M.; Kistayya, C. Eur. J. Med. Chem. 2010, 45, 2063.
Shirote, P.J.; Bhatia, M.S. Arab. J. Chem. 2011, 4, 413.
Padmavathi, V.; Sudhakar Reddy, G.; Padmaja, A.; Kondaiah, P.; Ali,
S. Eur. J. Med. Chem. 2009, 44, 2106.
Jakubkiene, V.; Burbuliene, M.; Udrenaite, E.; Garaliene, V.;
Vainilavicius, P. Pharmazie. 2002, 57, 610.
Idrees, G.A.; Aly, O.M.; Abuo-Rahma Gel, D.; Radwan, M,F. Eur. J.
Med. Chem. 2009, 44, 3973.
Hadady, Z.; Toth, M.; Somsak, L. ARKIVOC. 2004, 7, 140.
Jayashankar, B.; Lokanath Rai, M.; Baskaran, N.; Sathish, H.S. Eur. J.
Med. Chem. 2009, 44, 3898.
Bhandari, S.V.; Bothara, K.G.; Raut, M.K.; Patil, A.A.; Sarkate, A.P.;
Mokale, V.J. Bioorg. Med. Chem. Lett. 2008, 16, 1822.
Solyanik, G.I.; Experimental Oncol. 2011, 32, 181.
Naresh Kumar, R.; Poornachandra, Y.; Nagender, P.; Mallareddy, G.;
Ravi Kumar, N.; Ranjithreddy, P.; Ganesh Kumar C.; Narsaiah, B.
Eur. J. Med. Chem. 2016, 108, 68.
1
2
3
4
5
6
7
8
9
6a
6b
6c
6d
6e
6f
24.9 ± 0.26
29.2 ± 0.19
18.5 ± 0.25
26.2 ± 0.32
20.9 ± 0.31
19.6 ± 0.23
23.3 ± 0.37
9.8 ± 0.11
12.8 ± 0.22
20.8 ± 0.15
1.9 ± 0.11
23.1 ± 0.44 19.8 ± 0.26 18.2 ± 0.12
30.3 ± 0.38 31.6 ± 0.44 28.4 ± 0.38
17.7 ± 0.16 13.4 ± 0.18 20.2 ± 0.36
24.8 ± 0.18 31.1 ± 0.36 28.7 ± 0.21
22.2 ± 0.11 26.4 ± 0.34 18.7 ± 0.21
18.9 ± 0.52 17.7 ± 0.18 13.5 ± 0.16
22.1 ± 0.25 19.9 ± 0.16 20.5 ± 0.32
11.
1
1
2.
3.
1
1
1
4.
5.
6.
6g
6h
6i
8.2 ±0.36
9.5 ± 0.19
8.7 ± 0.22
10.1 ± 0.24 11.6 ± 0.36 9.9 ± 0.17
18.2 ± 0.18 17.6 ± 0.17 18.8 ± 0.16
1
0
6j
a
17.
5
-Fluoro uracil
1.6 ± 0.12
1.3 ± 0.09
1.8 ± 0.11
a
=
standard
1
8.
1
2
9.
0.
Table 4. Anticancer activity of 7a-k and 8a-d derivatives
IC50 values (μM)
21.
22.
Naresh Kumar, R.; Malla Reddy, G.; Nagender, P.; Kurumurthy, C.;
Shanthan Rao, P.; Santosh, K.; Sri Giridhar, K.; Narsaiah, B. J.
Heterocyclic Chem. 2014, 51, 1531.
Sambasiva Rao, P.; Rathnakar Reddy, K.; Nagender, P.; Naresh
Kumar, R.; Shanthan Rao, P.; Narsaiah, B. Chem. Lett. 2013, 42, 604.
Nita, M.E.; Nagawa, H.; Tominaga, O.; Tsuno, N.; Fujii, S.; Sasaki, S.;
Fu, C.G.; Takenoue, T.; Tsuruo, T.; Muto, T. Br. J. Cancer, 1998, 78,
S.No Compd
MDA MB-
HeLa
DU145
HepG2
2
31
2
3.
1
2
3
4
5
6
7
8
9
7a
7b
7c
7d
7e
7f
40.9 ± 0.52
-
50.2 ± 0.54
-
53.4 ± 0.46
-
39.8 ± 0.41
-
9
86.
36.6 ± 0.28
14.6 ± 0.18
23.1 ± 0.26
22.6 ± 0.22
21.9 ± 0.44
11.8 ± 0.23
13.9 ± 0.41
20.7 ± 0.15
31.4 ± 0.52
20.4 ± 0.34
14.8 ± 0.28
15.9 ± 0.24
17.0 ± 0.26
1.9 ± 0.11
40.2 ± 0.32
13.2 ± 0.28
20.2 ± 0.11
21.8 ± 0.18
15.6 ± 0.16
9.4 ± 0.11
14.2 ± 0.24
18.8 ± 0.48
30.5 ± 0.44
15.4 ± 0.48
10.7 ± 0.15
14.1 ± 0.32
15.5 ± 0.16
1.6 ± 0.12
35.4 ± 0.24
15.1 ± 0.33
22.4 ± 0.28
19.8 ± 0.27
14.5 ± 0.21
10.6 ± 0.32
12.1 ± 0.36
19.2 ± 0.22
32.2 ± 0.18
19.2 ± 0.22
11.2 ± 0.22
13.8 ± 0.23
14.1 ± 0.22
1.3 ± 0.09
29.8 ± 0.36
12.8 ± 0.45
23.9 ± 0.34
20.4 ± 0.32
20.1 ± 0.18
12.3 ± 0.17
11.8 ± 0.21
21.0 ± 0.38
26.6 ± 0.23
20.3 ± 0.45
13.5 ± 0.19
12.2 ± 0.33
18.2 ± 0.35
1.8 ± 0.11
24. Nasr, T.; Bondock, S.; Youns, M.; Eur. J. Med. Chem. 2016, 76, 539.
7g
7h
7i
1
0
1
2
3
4
5
7j
1
1
1
1
1
7k
8a
8b
8c
8d
a
5
-Fluorouracil
A
series of novel nicotinohydrazide and 1,3,4-oxadiazol-2-yl)-6-
(trifluoromethyl)pyridine derivatives synthesized, screened for anticancer
activity. Compounds 6h, 6i, 7d, 7h, 7i and 8b which showed highest activity
against DU145 (prostate), HepG2 (liver) cell lines have been identified.
Acknowledgements
Authors are thankful to the Council of Scientific and Industrial Research
(CSIR), New Delhi, India for the financial assistance in the form of XII five
year plan project DITSF code;CSC-0204. Authors (R. Naresh Kumar, Y.
Poornachandra, P Nagender, G. Santhosh Kumar, D. Krishna Swaroop) are
also thankful to CSIR for providing financial assistance in the form of
Research Fellowship and contingency grant.